Radiology and Radiation Oncology | Imaging Technology News itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WILLISTON PARK, N.Y., March 1, 2021 /PRNewswire/ North Shore Medical Labs (NSML) announced the operation of a drive-thru COVID-19 testing program at Roosevelt Field in Garden City, New York to support efforts to increase access to testing and help slow the spread of the virus. No appointment is required but encouraged. There is no cost to individuals to receive a test
1. All testing will be available on a first-come, first-served basis
2. Our goal is to make COVID-19 testing in the community easier to access and more convenient, said Ahsan Sheikh, Marketing Director of NSML. We recognize the critical role testing plays in helping to manage the spread of the virus and are incredibly proud of how our team has responded to this need while continuing to take care of our clients and patients. The drive-thru COVID-19 testing program will increase testing capacity and timely results in a safe environment to assist in combating the pandemic,
email article
After close to a decade at the helm, Richard Schilsky, MD, has retired from his role as chief medical officer of the American Society of Clinical Oncology (ASCO).
His legacy as the organization s first CMO will be what he calls the ASCO research enterprise launching ASCO s first-ever clinical trial, increasing its ability to conduct observational studies, and tapping into the 40,000-person membership for original survey-based research. It was clear that while ASCO was a tremendous vehicle to disseminate and amplify research findings that were generated by various entities, ASCO itself didn t actually do any research to contribute any knowledge to the field, Schilsky told
MAKO Medical Laboratories, in conjunction with the South Carolina Department of Health and Environmental Control (SCDHEC) has identified the first instance of the new variant of the novel coronavirus in the state. The partnership has found an occurrence of the B1.1.7 variant of COVID-19 in South Carolina. There have now been more than 300 cases of this particular variant found in 28 states across the country, according to the Centers for Disease Control (CDC).
Canton Daily Ledger
PEKIN Reditus Laboratories announced it has received accreditation from the College of American Pathologists (CAP). The application for CAP is a lengthy and time-consuming process that Reditus knew it could achieve under the direction of Dr. Joshua Geltz.
The CAP’s Laboratory Accreditation Program is recognized as the champion of laboratory excellence. The rigorous accreditation process which laboratories undergo to meet these requirements commonly exceed the standards of the Clinical Laboratory Improvement Amendments (CLIA), the U.S. Food and Drug Administration and the Occupational Safety and Health Administration. CAP’s areas of measure include laboratory safety, procedures, training, documentation, and personnel qualifications. The accreditation process also included an on-site visit of an inspection team of practicing lab professionals. Reditus Laboratories was able to meet these requirements with a perfect score in all areas assessed Jan. 28.